Hemogenyx Pharmaceuticals (LON:HEMO) Trading Up 10.3% – Here’s What Happened

Hemogenyx Pharmaceuticals Plc (LON:HEMO) was up 10.3% on Monday . The stock traded as high as GBX 1,040 and last traded at GBX 1,010. Approximately 41,022 shares traded hands during mid-day trading, an increase of 24% from the average daily volume of 33,059 shares. The stock had previously closed at GBX 916.

Hemogenyx Pharmaceuticals Price Performance

The company has a current ratio of 0.43, a quick ratio of 6.72 and a debt-to-equity ratio of -440.54. The firm has a market capitalization of £64.89 million, a PE ratio of -4.37 and a beta of 1.56. The business has a 50-day moving average of GBX 922.49 and a 200 day moving average of GBX 884.97.

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.